Indications
Velsipity is indicated for the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.
Composition
- Active substance
- Etrasimod arginine
- International name (INN)
- etrasimod
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Velsipity
- Active substance
- Etrasimod arginine
- ATC code
- L04AE05
- Therapeutic area
- Colitis, Ulcerative